75 related articles for article (PubMed ID: 19362973)
1. The epidemiology of Waldenström macroglobulinemia.
McMaster ML
Semin Hematol; 2023 Mar; 60(2):65-72. PubMed ID: 37099032
[TBL] [Abstract][Full Text] [Related]
2. Molecular pathogenesis of Waldenstrom's macroglobulinemia.
Braggio E; Philipsborn C; Novak A; Hodge L; Ansell S; Fonseca R
Haematologica; 2012 Sep; 97(9):1281-90. PubMed ID: 22773606
[TBL] [Abstract][Full Text] [Related]
3. Long-term outcomes by bone marrow B-cell depletion from the R2W trial of bortezomib with cyclophosphamide and rituximab in Waldenstrőm macroglobulinaemia.
de Tute R; Counsell N; Clifton-Hadley L; D'Sa S; Pratt G; Campbell G; Campbell L; Sadler R; Townsend W; Popova B; Smith P; Schofield O; Owen R; Auer R
Leukemia; 2024 Apr; 38(4):822-828. PubMed ID: 38409530
[TBL] [Abstract][Full Text] [Related]
4. A Phase II Study to Evaluate the Efficacy of Bortezomib in Combination with Thalidomide in Treatment-Naïve Waldenstrom Macroglobulinemia Patients.
Byun JM; Shin J; Kim SA; Park H; Lee J; Shin DY; Hong J; Lee JO; Bang SM; Kim I; Yoon SS; Koh Y
Cancer Res Treat; 2024 Apr; 56(2):675-680. PubMed ID: 37752793
[TBL] [Abstract][Full Text] [Related]
5. The BLIMP1-EZH2 nexus in a non-Hodgkin lymphoma.
Anderson KJ; Ósvaldsdóttir ÁB; Atzinger B; Traustadóttir GÁ; Jensen KN; Lárusdóttir AE; Bergthórsson JT; Hardardóttir I; Magnúsdóttir E
Oncogene; 2020 Jul; 39(28):5138-5151. PubMed ID: 32533097
[TBL] [Abstract][Full Text] [Related]
6. Onsets of progression and second treatment determine survival of patients with symptomatic Waldenström macroglobulinemia.
Guidez S; Labreuche J; Drumez E; Ysebaert L; Bakala J; Delette C; Hivert B; Protin C; Declercq H; Verlay M; Marolleau JP; Duhamel A; Morel P;
Blood Adv; 2018 Nov; 2(22):3102-3111. PubMed ID: 30455359
[TBL] [Abstract][Full Text] [Related]
7. What should be the goal of therapy for Waldenström macroglobulinemia patients? Complete response should be the goal of therapy.
Treon SP; Castillo JJ
Blood Adv; 2017 Nov; 1(25):2486-2490. PubMed ID: 29296899
[No Abstract] [Full Text] [Related]
8. Penile ulcer as a specific clinical manifestation of Waldenstrom's macroglobulinemia.
Oliveira CC; Bressa JA; Mendes F; Roncada EV; Monteiro R; Abreu MA
An Bras Dermatol; 2016 Apr; 91(2):236-8. PubMed ID: 27192528
[TBL] [Abstract][Full Text] [Related]
9. Immunophenotyping of Waldenströms macroglobulinemia cell lines reveals distinct patterns of surface antigen expression: potential biological and therapeutic implications.
Paulus A; Chitta KS; Wallace PK; Advani PP; Akhtar S; Kuranz-Blake M; Ailawadhi S; Chanan-Khan AA
PLoS One; 2015; 10(4):e0122338. PubMed ID: 25853860
[TBL] [Abstract][Full Text] [Related]
10. Persistent monotypic plasma cells with absence of neoplastic B cell component in a treated case of waldenström macroglobulinemia: a sign of residual disease?
Gajendra S; Sachdev R; Jha B; Goel S; Sahni T
J Clin Diagn Res; 2014 Nov; 8(11):FD12-3. PubMed ID: 25584235
[TBL] [Abstract][Full Text] [Related]
11. [B-cell neoplasms with plasmacellular and plasmablastic differentiation].
Fend F; Quintanilla-Martínez L
Pathologe; 2013 May; 34(3):198-209. PubMed ID: 23462793
[TBL] [Abstract][Full Text] [Related]
12. Development and characterization of a novel human Waldenström macroglobulinemia cell line: RPCI-WM1, Roswell Park Cancer Institute - Waldenström Macroglobulinemia 1.
Chitta KS; Paulus A; Ailawadhi S; Foster BA; Moser MT; Starostik P; Masood A; Sher T; Miller KC; Iancu DM; Conroy J; Nowak NJ; Sait SN; Personett DA; Coleman M; Furman RR; Martin P; Ansell SM; Lee K; Chanan-Khan AA
Leuk Lymphoma; 2013 Feb; 54(2):387-96. PubMed ID: 22812491
[TBL] [Abstract][Full Text] [Related]
13. Assessment of bone marrow response in Waldenström's macroglobulinemia.
Varghese AM; Rawstron AC; Ashcroft AJ; Moreton P; Owen RG
Clin Lymphoma Myeloma; 2009 Mar; 9(1):53-5. PubMed ID: 19362973
[TBL] [Abstract][Full Text] [Related]
14. Fludarabine therapy in a patient with progressive symptomatic Waldenström's macroglobulinemia.
Hałaburda K; Hellmann A
Acta Haematol Pol; 1994; 25(1):63-7. PubMed ID: 8209618
[TBL] [Abstract][Full Text] [Related]
15. Delayed response to fludarabine in lymphoplasmacytic lymphoma/Waldenström's macroglobulinemia.
Del Giudice I; Matutes E; Osuji N; Parry-Jones N; Swansbury J; Catovsky D
Haematologica; 2005 Feb; 90(2):268-70. PubMed ID: 15710588
[TBL] [Abstract][Full Text] [Related]
16. Phase 2 study of ofatumumab, fludarabine and cyclophosphamide in relapsed/refractory Waldenström's macroglobulinemia.
Gavriatopoulou M; Kastritis E; Kyrtsonis MC; Vassilakopoulos TP; Roussou M; Fotiou D; Migkou M; Mpakiri M; Tasidou A; Terpos E; Dimopoulos MA
Leuk Lymphoma; 2017 Jun; 58(6):1506-1508. PubMed ID: 27724158
[No Abstract] [Full Text] [Related]
17. Rituximab-based treatments in Waldenström's macroglobulinemia.
Dimopoulos MA; Kastritis E; Roussou M; Eleutherakis-Papaiakovou E; Migkou M; Gavriatopoulou M; Tassidou A; Terpos E
Clin Lymphoma Myeloma; 2009 Mar; 9(1):59-61. PubMed ID: 19362975
[TBL] [Abstract][Full Text] [Related]
18. Fludarabine-based combination therapies for Waldenström's macroglobulinemia.
Tedeschi A; Alamos SM; Ricci F; Greco A; Morra E
Clin Lymphoma Myeloma; 2009 Mar; 9(1):67-70. PubMed ID: 19362977
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
